Search

Zentalis Pharmaceuticals Inc

Slēgts

3.88 0.52

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.81

Max

3.92

Galvenie mērījumi

By Trading Economics

Ienākumi

-42M

-78M

EPS

-0.59

Darbinieki

106

EBITDA

-42M

-77M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+127.58% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 6. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

25M

356M

Iepriekšējā atvēršanas cena

3.36

Iepriekšējā slēgšanas cena

3.88

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 26. aug. 23:56 UTC

Fluence Energy Inc shares are higher in after-market trading. Broader market context includes recent PCE price index data indicating ongoing inflationary pressures.

2026. g. 26. aug. 23:56 UTC

Correlated Moves
Social Media

Tesla shares are trading higher in after-market hours, supported by increased institutional holdings from major investors and a broader market uptick.

2026. g. 26. aug. 23:56 UTC

Shares of Stanley Black & Decker Inc rose modestly in after-market trading, settling at a cumulative return of 0.33% since Wednesday's close.

2026. g. 26. aug. 23:56 UTC

Shares of Synchrony Financial are lower in after-market trading, moving from an early high to a low during the session.

2026. g. 26. aug. 23:56 UTC

RTX Corp. shares are trading lower in after-market hours, with significant volatility noted since Wednesday's close and prices below the 20-day moving average.

2026. g. 26. aug. 23:56 UTC

Macro Event

EUR/AUD trades lower as Australia's July inflation rate declines to 3.5%, exceeding expectations. The currency pair remains near the lower end of its one-month range.

2026. g. 26. aug. 23:56 UTC

Ralph Lauren Corp shares are lower in after-market hours, continuing a trend from regular trading. The stock remains below its 20-day moving average.

2026. g. 26. aug. 23:56 UTC

News

Constellation Brands reported first-quarter results that beat expectations, driven by beer sales. The company also reaffirmed EPS guidance and plans a $100 million investment.

2026. g. 26. aug. 23:56 UTC

Cheniere Energy shares are trading lower in after-market hours. No specific news was identified to explain this price movement.

2026. g. 26. aug. 23:52 UTC

AT&T Inc shares are lower in after-market hours with no specific news identified. Broader market data on rising consumer prices may influence investor sentiment.

2026. g. 26. aug. 23:52 UTC

MARA Holdings Inc. shares are higher in after-market hours, supported by robust economic data and easing crude oil prices, reflecting a positive market trend.

2026. g. 26. aug. 23:52 UTC

Correlated Moves

The SGD/CHF is trading higher, supported by a recent rise in USD/CHF. It remains near the upper end of its one-month trading range.

2026. g. 26. aug. 23:52 UTC

The Swiss franc is trading lower against the South African rand during Wednesday's session, remaining near the lower end of its one-month range.

2026. g. 26. aug. 23:51 UTC

The Nikkei 225 Index is trading higher in after-market hours, continuing a trend of upward movement following Wednesday's close.

2026. g. 26. aug. 23:51 UTC

Ladder Capital Corp shares are higher in after-market trading, moving up from earlier lows and trading above its 20-day moving average. No specific news identified.

2026. g. 26. aug. 23:51 UTC

Correlated Moves

Alpha and Omega Semiconductor rises in after-hours trading, recovering from an earlier dip. The stock advanced sharply since Wednesday's close, tracking semiconductor sector gains.

2026. g. 26. aug. 23:51 UTC

Correlated Moves

PagerDuty Inc. shares are higher in after-market hours, driven by strong overall market momentum and Salesforce Inc.'s significant gain. Positive economic data supports this trend.

2026. g. 26. aug. 23:51 UTC

Cabaletta Bio Inc shares are lower in after-market trading, following a decline earlier in the session. No specific news was identified to explain the movement.

2026. g. 26. aug. 23:51 UTC

JetBlue Airways Corp shares are higher in after-market trading, reflecting broader market gains amid positive economic data on consumer prices and durable goods orders.

2026. g. 26. aug. 23:51 UTC

Community Financial System Inc shares are higher in after-market hours, recovering from earlier lows. The stock remains below its 20-day moving average.

2026. g. 26. aug. 23:51 UTC

Beam Therapeutics Inc shares are higher in after-market hours, reflecting a broadly positive market trend. The stock is near the upper end of its one-month range.

2026. g. 26. aug. 23:51 UTC

Arbor Realty Trust is trading higher in after-market hours, advancing from Wednesday's close. Shares earlier pulled back but remain above the prior close.

2026. g. 26. aug. 23:51 UTC

Yelp Inc shares are higher in after-market trading, recovering from an earlier dip. The stock remains below its 20-day moving average.

2026. g. 26. aug. 23:51 UTC

PENN Entertainment Inc. shares rose in after-market trading, gaining modestly since Wednesday's close despite remaining below its 20-day moving average.

2026. g. 26. aug. 23:51 UTC

U.S. markets gain momentum as inflation data reveals slight consumer price rise, while UK car production declines and copper prices surge amid strong demand.

2026. g. 26. aug. 23:51 UTC

U.S. equity indices rise amid positive global sentiment and inflation data, while investors await Nvidia earnings and navigate geopolitical tensions affecting oil prices.

2026. g. 26. aug. 23:51 UTC

Asia equity markets rise on falling crude oil prices and tech stock gains, while caution prevails ahead of U.S. inflation data and Fed Chair's speech.

2026. g. 26. aug. 23:51 UTC

Mixed trading in European equities as easing inflation concerns clash with rising energy prices and UK economic woes.

2026. g. 26. aug. 23:51 UTC

Brazil's Q2 GDP Growth Rate Expected to Rise by 0.8% Amidst Global Economic Challenges, Following a Strong 1.1% Expansion in Q1

2026. g. 26. aug. 23:51 UTC

Market Cautiously Awaits Insights from Jackson Hole Symposium as Inflation Concerns and Fed Dissent Shape Economic Outlook.

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

127.58% augšup

Prognoze 12 mēnešiem

Vidējais 8.83 USD  127.58%

Augstākais 11 USD

Zemākais 5 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

5

Pirkt

1

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat